Your browser doesn't support javascript.
loading
Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.
Crooks, Ema T; Grimley, Samantha L; Cully, Michelle; Osawa, Keiko; Dekkers, Gillian; Saunders, Kevin; Rämisch, Sebastian; Menis, Sergey; Schief, William R; Doria-Rose, Nicole; Haynes, Barton; Murrell, Ben; Cale, Evan Mitchel; Pegu, Amarendra; Mascola, John R; Vidarsson, Gestur; Binley, James M.
Afiliación
  • Crooks ET; San Diego Biomedical Research Institute, San Diego, California, United States of America.
  • Grimley SL; San Diego Biomedical Research Institute, San Diego, California, United States of America.
  • Cully M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Osawa K; San Diego Biomedical Research Institute, San Diego, California, United States of America.
  • Dekkers G; Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Saunders K; Duke University Medical Center, Durham, North Carolina, United States of America.
  • Rämisch S; The Scripps Research Institute, Department of Immunology and Microbial Science, La Jolla, California, United States of America.
  • Menis S; IAVI Neutralizing Antibody Center, The Scripps Research Institute, Department of Immunology and Microbial Science, La Jolla, California, United States of America.
  • Schief WR; The Scripps Research Institute, Department of Immunology and Microbial Science, La Jolla, California, United States of America.
  • Doria-Rose N; IAVI Neutralizing Antibody Center, The Scripps Research Institute, Department of Immunology and Microbial Science, La Jolla, California, United States of America.
  • Haynes B; The Scripps Research Institute, Department of Immunology and Microbial Science, La Jolla, California, United States of America.
  • Murrell B; IAVI Neutralizing Antibody Center, The Scripps Research Institute, Department of Immunology and Microbial Science, La Jolla, California, United States of America.
  • Cale EM; Ragon Institute, Cambridge, Massachusetts, United States of America.
  • Pegu A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Mascola JR; Duke University Medical Center, Durham, North Carolina, United States of America.
  • Vidarsson G; Department of Medicine, University of California San Diego, San Diego, California, United States of America.
  • Binley JM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
PLoS Pathog ; 14(5): e1007024, 2018 05.
Article en En | MEDLINE | ID: mdl-29718999
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteína gp41 de Envoltorio del VIH / Proteína gp120 de Envoltorio del VIH / VIH-1 / Anticuerpos Neutralizantes Límite: Humans Idioma: En Revista: PLoS Pathog Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteína gp41 de Envoltorio del VIH / Proteína gp120 de Envoltorio del VIH / VIH-1 / Anticuerpos Neutralizantes Límite: Humans Idioma: En Revista: PLoS Pathog Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos